News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. annual CPI rose to 3.8% in April, lifting bond yields and pulling the S&P 500 and Nasdaq lower.
  • Semiconductor stocks plunged, weighing on the Nasdaq and accelerating the broader equities sell-off.
  • American Electric Power arranged a $2.6 billion equity offering via two-year forward sales, and shares fell about 3% after-hours.
  • FCC approved EchoStar's $40 billion wireless-spectrum sale to SpaceX and AT&T, adding build conditions and a $2.4 billion escrow.
  • Anthropic is seeking at least $30 billion in funding at a pre-money valuation above $900 billion while exploring an October IPO.
  • USDA excluded ten lenders from its Rural Development program over compliance, removing roughly $620 million in delinquent-loan exposure.
  • S&P moved Mexico's outlook to negative while maintaining BBB ratings, citing fiscal strain and state-energy support risks.

Latest Articles

InfuSystem CEO Increases Equity Position via Open Market Purchases

InfuSystem CEO Increases Equity Position via Open Market Purchases

Carrie Lachance, the President and Chief Executive Officer of InfuSystem Holdings, Inc. (NASDAQ: INFU), has expanded her ownership stake in the company through two distinct open market transactions. These purchases occurred in May 2026, signaling a direct investment by top leadership at a time when the company's stock has faced recent downward pres…

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation announced the presentation of the first real-world evidence study of RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the EHA 2026 Congress. The study, conducted at Moffitt Cancer Center, demonstrated safety and clinical efficacy consistent with the Phase 3 IMerge trial, including in heavily tr…

Analysts Expect Stability, Few Breakthroughs from Trump-Xi Beijing Meeting

Analysts Expect Stability, Few Breakthroughs from Trump-Xi Beijing Meeting

Analysts say the Beijing summit between President Donald Trump and President Xi Jinping is more likely to reinforce a fragile détente than to produce sweeping new agreements. Modest, market-oriented deliverables - such as Chinese purchases of U.S. farm goods and aircraft, eased rare earth restrictions, or the formation of a bilateral trade board - …

Uniti Wholesale Accelerates with FastWaves™

Uniti Wholesale Accelerates with FastWaves™

Uniti Wholesale has quickly demonstrated strong demand for its FastWaves service, securing a customer for eight 400G circuits just two weeks after launch and delivering circuits in 14 days. FastWaves addresses the market need for faster wavelength delivery, particularly driven by AI workloads, hyperscalers, neocloud providers, and large enterprises…

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion A/S announced that it will present new preclinical data for EVX-04, an AI-designed off-the-shelf therapeutic vaccine targeting endogenous retroviral antigens in acute myeloid leukemia (AML), at the European Hematology Association 2026 Congress. The data demonstrate EVX-04's immune response capabilities and tumor growth prevention in preclin…

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Moleculin Biotech announced that an independent review by the Cleveland Clinic of pooled data from five clinical trials demonstrates that Annamycin, their next-generation anthracycline for relapsed/refractory acute myeloid leukemia (R/R AML), does not cause clinically significant cardiotoxicity even at cumulative doses exceeding conventional anthra…

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios Pharmaceuticals announced new detailed data presentations of mitapivat at the 31st European Hematology Association Congress (EHA 2026). Results from the pivotal RISE UP Phase 3 trial in sickle cell disease demonstrate significant hemoglobin improvements and anti-hemolytic effects. Additional positive long-term data from ENERGIZE trials in tha…

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam Therapeutics announced it will present updated Phase 1/2 clinical trial data for ristoglogene autogetemcel (risto-cel), an investigational gene-edited cell therapy aimed at treating sickle cell disease (SCD). The data underscores risto-cel's potential to restore red blood cell health and improve disease pathology by inducing fetal hemoglobin p…

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences announced that two of its investigational allogeneic CAR-T cell therapies, vispa-cel and CB-011, will be featured in oral presentations at the 2026 European Hematology Association Annual Meeting. These presentations will share updated clinical trial data demonstrating the therapies' potential in treating relapsed or refractory B…

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine announced multiple presentations at the European Hematology Association (EHA) 2026 Congress, including an oral presentation of phase 2 RALLY-MF trial data for DISC-0974 targeting anemia in myelofibrosis patients. The company also highlighted updates on bitopertin in erythropoietic protoporphyria (EPP) and ongoing trials for polycythem…

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences announced multiple presentations at the European Hematology Association (EHA) 2026 Congress, including pivotal oral presentation data from the APEX trial of bezuclastinib in Advanced Systemic Mastocytosis and preclinical data for their JAK2 V617F inhibitor program. These presentations underscore the company's progress in developi…

Pentagon Says U.S. Military Operations in Iran Have Cost $29 Billion So Far

Pentagon Says U.S. Military Operations in Iran Have Cost $29 Billion So Far

A senior Pentagon official told lawmakers that U.S. military activity in Iran has reached $29 billion in costs, up $4 billion from an estimate issued in late April. The updated total covers repair and replacement of equipment and operational expenses, but Pentagon officials have not provided a detailed breakdown of the added $4 billion. Lawmakers r…